In its organising meeting, the Board of Directors of Orion Corporation, which was elected today by the Annual General Meeting of the Shareholders, has elected Timo Maasilta as Vice Chairman.
The compositions of the Board committees were decided to be as follows:
Mikael Silvennoinen, Chairman
Ari Lehtoranta, Chairman
Kari Jussi Aho
Hilpi Rautelin, Chairman
Kari Jussi Aho
The members to the Nomination Committee were elected on 28 October 2019 as stated in the Stock Exchange Release on the same day.
All members of the Board of Directors have been assessed to be independent of the company and its significant shareholders.
President and CEO
SVP, Corporate Functions
Olli Huotari, Senior Vice President, Corporate Functions
Phone +358 50 966 3054
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.